GURUGRAM, India, March 30, 2022 /PRNewswire/ — Testimony to the world-class healthcare provided by the hospital, Medanta Gurugram, operated by Global Health Limited, (https://www.medanta.org/) has been ranked as the best private hospital in India for the third consecutive time in a global survey conducted by Newsweek in partnership with Statista Inc. Medanta is the only private hospital in India to feature in the top 150 of the World’s Best Hospitals 2022 survey list.
Conducted across over 2,200 hospitals in 27 countries, the survey is based on recommendations from medical professionals, results from patient surveys and medical key performance indicators. This includes recommendations from over 8,00,000 medical experts (doctors, hospitals managers, healthcare professionals), publicly available data from existing patient surveys and medical key performance indicators such as quality of treatment and hygiene measures.
Speaking on the recognition, Dr. Naresh Trehan, Chairman and Managing Director, Medanta, said, ”Being recognized as the best private hospital in India for three consecutive years is a testimony to the standards of clinical care delivered by our team of highly accomplished doctors and staff, world-class medical infrastructure, and advanced medical technology that we offer. While the world was disrupted with COVID-19, Medanta was quick to adapt and evolve, and strived to provide full spectrum of healthcare services in a safe environment across all super specialties. We are honored to receive this recognition from a reputed and independent platform like Newsweek and will continue furthering our commitment to making world-class healthcare accessible to all.”
Link to the survey: World’s Best Hospitals 2022 – India (newsweek.com)
Founded by Dr. Naresh Trehan, a world-renowned cardiovascular and cardiothoracic surgeon who has been awarded the prestigious Padma Bhushan and the Padma Shri, the third and fourth-highest civilian awards in India and the B C Roy award in recognition of his distinguished contribution to medicine, Global Health Limited (the “Company“) is one of the largest private multi-speciality tertiary care providers operating in the North and East regions of India, with key specialties of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopaedics, liver transplant, and kidney and urology, according to the report titled ‘An assessment of the healthcare delivery market in India, September 2021‘ by CRISIL Limited.
Under the “Medanta” brand, the Company has a network of five hospitals currently in operation (Gurugram, Indore, Ranchi, Lucknow, and Patna). Spanning an area of 3.7 million sq. ft., its operational hospitals have 2,176 installed beds as on March 31, 2021. It also has one hospital planned for development in Noida. As of March 31, 2021, the Company provides healthcare services in over 30 medical specialties and engages over 1,100 doctors led by highly experienced department heads. The Company’s facilities have received national and international accreditations, including the NABH accreditation for the hospital and blood bank at Gurugram. The Gurugram hospital was also featured in the list of world’s best specialized hospitals for cardiology in 2021 and cardiology and neurology in 2022 rankings released by Newsweek.
Certain Information in this press release is from the report titled ‘An assessment of the healthcare delivery market in India, September 2021‘ by CRISIL Limited, which is subject to the following disclaimer:
CRISIL Research, a division of CRISIL Limited (CRISIL) has taken due care and caution in preparing this report (Report) based on the Information obtained by CRISIL from sources which it considers reliable (Data). CRISIL does not guarantee the accuracy, adequacy or completeness of any material contained in or referred to in Report. This Report is not a recommendation to invest / disinvest in any entity covered in the Report and no part of this Report should be construed as an expert advice or investment advice or any form of investment banking within the meaning of any law or regulation. CRISIL especially states that it has no liability whatsoever to the subscribers / users / transmitters/ distributors of this Report. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary permission and/or registration to carry out its business activities in this regard. Global Health Limited will be responsible for ensuring compliances and consequences of non-compliances for use of the Report or part thereof outside India. CRISIL Research operates independently of, and does not have access to information obtained by CRISIL Ratings Limited / CRISIL Risk and Infrastructure Solutions Ltd (CRIS), which may, in their regular operations, obtain information of a confidential nature. The views expressed in this Report are that of CRISIL Research and not of CRISIL Ratings Limited / CRIS. No part of this Report may be published/reproduced in any form without CRISIL’s prior written approval.
Global Health Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its equity shares (“Offer“) and has filed a Draft Red Herring Prospectus (“DRHP“) with the Securities and Exchange Board of India (“SEBI“). The DRHP is available on the website of the SEBI at www.sebi.gov.in, the website of the National Stock Exchange of India Limited at www.nseindia.com and the website of the BSE Limited at www.bseindia.com and the respective websites of the book running lead managers to the Offer, Kotak Mahindra Capital Company Limited at https://investmentbank.kotak.com, Jefferies India Private Limited at https://www.jefferies.com, Credit Suisse Securities (India) Private Limited at https://www.credit-suisse.com/in/en/investment-banking-apac/investment-banking-in-india/ipo.html and JM Financial Limited at www.jmfl.com. Investors should note that investment in equity shares involves a high degree of risk. For details, potential investors should refer to the Red Herring Prospectus which may be filed with the Registrar of Companies, National Capital Territory of Delhi & Haryana in the future, including the section titled “Risk Factors”. Potential investors should not rely on the DRHP filed with the SEBI in making any investment decision. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act“), and may not be offered or sold within the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are only being offered and sold (i) within the United States to “qualified institutional buyers” (as defined in Rule 144A and referred to in the Draft Red Herring Prospectus as “U.S. QIBs“) pursuant to private transactions exempt from the registration requirements of the U.S. Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S and the applicable laws of the jurisdiction where those offers and sales occur. There will be no public offering of the Equity Shares in the United States.
The content is by PR NewsWire. DKODING Media is not responsible for the content provided or any links related to this content. DKODING Media is not responsible for the correctness, topicality or the quality of the content.